Reproductive gene editing imperils universal human rights
By Marcy Darnovsky, Leah Lowthorp, and Katie Hasson,
OpenGlobalRights
| 02. 15. 2018
What do recent advances in molecular genetics have to do with human rights? Quite a lot, it turns out. And key human rights documents have recognized this for some time.
Over the past few years, new “gene editing” tools that are cheaper, easier to use, and more accurate than previous ways to change living organisms’ DNA have rapidly spread to labs around the world. Scenarios that previously seemed far-fetched or far off now confront us, including the prospect of directly controlling the genes and traits that are passed down to future children and generations. Since 2015, a half dozen research teams, in China, the UK, and the United States, have separately reported efforts to modify specific genes in human embryos. These developments have brought us to a critical juncture: human reproductive gene editing now poses a threat to the human rights of future generations.
Gene editing for human reproduction carries huge social risks. It has the potential to threaten the health and autonomy of future generations, to exacerbate existing social disparities, and to lay the basis for a new market-based...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...